TYRA trades 105.2% below Wall Street's consensus target of $43.40.
Last 12 months price action with 12-month analyst target path
The base valuation assumes TYRA achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 7 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of November 8, 2026, Tyra Biosciences, Inc. (TYRA) has a Wall Street consensus price target of $43.40, based on estimates from 7 covering analysts. With the stock currently trading at $21.15, this represents a potential upside of +105.2%. The company has a market capitalization of $1.26B.
Analyst price targets range from a low of $29.00 to a high of $56.00, representing a 62% spread in expectations. The median target of $42.00 aligns closely with the consensus average. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 7 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, TYRA trades at a trailing P/E of -9.4x. Analysts expect EPS to grow -17.8% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 KROSKeros Therapeutics, Inc. | $300M | $9.36 | $20.33 | +117.2% | Buy | — | 17 |
 PRAXPraxis Precision Medicines, Inc. | $7.7B | $277.62 | $611.69 | +120.3% | Buy | — | 18 |
 ERASErasca, Inc. | $5.0B | $14.41 | $21.43 | +48.7% | Buy | — | 11 |
 RGENRepligen Corporation | $9.8B | $173.49 | $198.00 | +14.1% | Buy | 83.7x | 24 |
 ICLRICON Public Limited Company | $15.7B | $204.74 | $217.69 | +6.3% | Buy | 19.3x | 30 |
 CRLCharles River Laboratories International, Inc. | $16.3B | $337.52 | $308.36 | -8.6% | Buy | 29.7x | 37 |
 MEDPMedpace Holdings, Inc. | $18.2B | $653.11 | $646.90 | -1.0% | Hold | 35.8x | 19 |
 ARVNArvinas, Inc. | $414M | $6.41 | $14.00 | +118.4% | Buy | 90.0x | 26 |
 KYMRKymera Therapeutics, Inc. | $10.8B | $131.73 | $141.53 | +7.4% | Buy | — | 27 |
 VKTXViking Therapeutics, Inc. | $3.1B | $26.84 | $82.00 | +205.5% | Buy | — | 24 |
Quick answers to the most common questions about buying TYRA stock.
The consensus Wall Street price target for TYRA is $43.4, representing 105.2% upside from the current price of $21.15. With 7 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
TYRA has a consensus rating of "Buy" based on 7 Wall Street analysts. The rating breakdown is predominantly bullish, with 7 Buy/Strong Buy ratings. The consensus 12-month price target of $43.4 implies 105.2% upside from current levels.
TYRA's current price is $21.15 with a consensus target of $43.4 (105.2% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $56 for TYRA, while the most conservative target is $29. The consensus of $43.4 represents the median expectation. These targets typically reflect 12-month expectations.
TYRA is moderately covered, with 7 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 7 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month TYRA stock forecast based on 7 Wall Street analysts shows a consensus price target of $43.4, with estimates ranging from $29 (bear case) to $56 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on TYRA, with a "Buy" consensus rating and $43.4 price target (105.2% upside). 7 of 7 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
TYRA analyst price targets range from $29 to $56, a 62% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $43.4 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.